Home Blog Page 2718

Devicie Expands Global Channel Reach by Joining the Pax8 Marketplace

Devicie Intune deployment and maintenance solutions for Microsoft environments are now accessible to Pax8’s 40,000+ managed service providers

TAMPA BAY, Fla., Sept. 9, 2025 /PRNewswire/ — Devicie, a leader in optimized Microsoft Intune deployment and maintenance solutions, today announced that its solutions are now available in the Pax8 Marketplace, the leading cloud commerce Marketplace. With a promise of Intune automation, Intune at scale, and Intune that just works, this expansion gives managed service providers (MSPs) and their customers around the globe even easier access to Devicie’s automation and orchestration capabilities.

For many MSPs, managing Intune across multiple tenants is still highly manual, inconsistent, and reliant on scarce specialists, making it difficult to scale profitably while keeping customers secure and compliant. Devicie solves these challenges by automating deployment, standardizing management across tenants, and giving MSPs consistent visibility and reporting.

Devicie Expands Global Channel Reach by Joining the Pax8 Marketplace
Devicie Expands Global Channel Reach by Joining the Pax8 Marketplace

“Our mission has always been to reduce complexity and make modern management with Microsoft Intune effortless for IT teams and MSPs,” said Colin Britton, COO at Devicie. “By joining the Pax8 Marketplace, we’re giving more than 40,000 MSPs the ability to seamlessly adopt Devicie alongside their existing cloud solutions. This is about Intune automation, at scale, that just works, enabling MSPs to scale profitably, deliver consistent outcomes, and free up their teams for more strategic services.”

Devicie’s optimized deployment and maintenance platform reduces the time and complexity of endpoint management, providing out-of-the-box configurations, policies, permissions, and security protocols for Microsoft Intune environments. What typically takes 30–60 hours to configure manually can now be assessed in minutes with Devicie. Its multi-tenant solution enables MSPs to efficiently and consistently manage devices across multiple clients with zero-touch configuration, automatic updates, application patching, built-in remediation, and enhanced compliance reporting.

“At Pax8, our mission is to empower MSPs to deliver world-class solutions to SMBs worldwide,” said Oguo Atuanya, Corporate Vice President of Vendor Experience at Pax8. “Adding Devicie to the Pax8 Marketplace strengthens our ecosystem with powerful automation for Microsoft Intune and M365 environments, helping partners increase efficiency, enhance security and scale their businesses.”

With Devicie now in Pax8’s Marketplace, MSPs gain direct access to a platform that accelerates cloud-native IT operations while freeing resources to focus on high-value projects and services.

About Devicie

Intune automation. Intune at scale. Intune that just works.

Devicie transforms Microsoft Intune into an automated, always-optimized endpoint management platform. With zero-touch configuration, advanced security, built-in compliance reporting, and ongoing optimization, Devicie eliminates complexity and accelerates outcomes for IT teams and managed service providers. By reducing manual workloads and standardizing management across tenants, Devicie helps organizations scale securely, improve profitability, and free technical teams to focus on higher-value initiatives.

Devicie is available globally through trusted distribution partners including Pax8, TD SYNNEX, Microsoft, and Crayon. Learn more at www.devicie.com.

About Pax8

Pax8 is the technology Marketplace of the future, linking partners, vendors and small-to-midsized businesses (SMBs) through AI-powered insights and comprehensive product support. With a global partner ecosystem of over 40,000 managed service providers, Pax8 empowers SMBs worldwide by providing software and services that unlock their growth potential and enhance their security. Committed to innovating cloud commerce at scale, Pax8 drives customer acquisition and solution consumption across its entire ecosystem.
Follow Pax8 on Blog, Facebook, LinkedIn, X, and YouTube.

Media Contacts:

Miluse Vejdani, Channel Marketing Director, +1 (617) 640-3802, Miluse.vejdani@devicie.com

Product or service names mentioned herein may be the trademarks of their respective owners.

###

CAS introduces CAS IP Finder for improved intellectual property search

The AI-enhanced solution deepens search capabilities and improves user experience 

COLUMBUS, Ohio, Sept. 9, 2025 /PRNewswire/ — CAS, a division of the American Chemical Society specializing in scientific knowledge management, announces the introduction of CAS IP Finder, powered by STN™. This new intellectual property search solution expands on the trusted foundation of CAS STNext®, the premier scientific IP information platform for expert-level precision search across scientific and patent databases. CAS STNext supports intellectual property professionals with advanced capabilities, connecting users to a comprehensive collection of global databases, scientist-curated content, and patent information with precision search and analysis tools.

 

CAS IP Finder™ introduces AI-enhanced features and expanded content to make precision search more accessible across broader teams. The solution launches in fall 2025, with additional capabilities to follow. Developed to support evolving organizational search needs in intellectual property, CAS IP Finder enables organizations to uncover insights faster, reduce risk, and make confident decisions.

Patent volume continues to grow, scientific disciplines are increasingly interconnected, and complex subject matter makes patent research more challenging. Users of intellectual property search tools have traditionally had to choose between comprehensive and easy-to-use solutions, creating risks of missed prior art, legal disputes, and investments in unpatentable technologies. CAS IP Finder eliminates that compromise by connecting users of all experience levels to deeper content and precise search tools through user-friendly access points.

 “We designed CAS IP Finder to meet the growing demand for more intuitive, high-performance search tools in intellectual property,” said Tim Wahlberg, Chief Product Officer, CAS. “By integrating AI-enhanced capabilities and expanding access to curated content, we are enabling broader teams across the enterprise to conduct high-quality searches, uncover insights faster, and collaborate more effectively.”

CAS IP Finder introduces capabilities that support high-quality intellectual property search and analysis:  

  • Integrated access to more than 100 scientific, patent, and non-patent literature databases.
  • Expanded life sciences content, including SAR, ADME, and toxicity data.
  • Flexible search pathways, including multi-file command line, point-and-click query builder, best-in-class structure search, and AI-enhanced exploratory search.
  • New analysis and visualization tools.
  • Enhanced reporting capabilities for sharing and collaboration.

These enhancements support a range of professionals, including IP professionals, patent attorneys, business strategists, and R&D leaders/scientists, by making precision search more intuitive and accessible across the enterprise.

“As scientific and patent data grow in complexity, volume, and global reach, organizations need comprehensive IP search solutions to succeed. CAS IP Finder delivers a complete view of the IP landscape and makes high-quality insights accessible to more users, enabling confident decisions, reduced risk, and accelerated innovation,” said Manuel Guzman, President, CAS.

For more information on CAS IP Finder, visit CAS IP Finder.

About CAS 

CAS connects the world’s scientific knowledge to accelerate breakthroughs that improve lives. We empower global innovators to efficiently navigate today’s complex data landscape and make confident decisions in each phase of the innovation journey. As a specialist in scientific knowledge management, our team builds the largest authoritative collection of human-curated scientific data in the world and provides essential information solutions, services, and expertise. Scientists, patent professionals, and business leaders across industries rely on CAS to help them uncover opportunities, mitigate risks, and unlock shared knowledge so they can get from inspiration to innovation faster. CAS is a division of the American Chemical Society. Connect with us at cas.org.

Social options:

  1. Introducing CAS IP Finder™: AI-enhanced precision search for intellectual property. Access deeper content, intuitive tools, and expanded life sciences data. Learn more: https://www.cas.org/solutions/stn-ip-protection-suite/ip-finder
  2. CAS IP Finder™ delivers AI-enhanced precision search, expanded life sciences data, and intuitive tools for confident decisions and accelerated innovation. Explore the future of IP search: https://www.cas.org/solutions/stn-ip-protection-suite/ip-finder

 

Metabolon Partners with China Kadoorie Biobank to Advance Precision Health

The landmark multiomics study will examine how lifestyle, environmental, socioeconomic, and genetic factors play a significant role in shaping common diseases

MORRISVILLE, N.C., Sept. 9, 2025 /PRNewswire/ — Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, announced today it was chosen by the China Kadoorie Biobank (CKB) to profile plasma metabolomics biomarkers, using Metabolon’s Global Discovery Panel™. CKB is one of the world’s largest and most comprehensive cohort studies to examine how lifestyle, environmental, genetic, and socioeconomic factors play a significant role in shaping common diseases. CKB is a long-term collaborative project established during 2004-08 between the University of Oxford and various partners in China, including Peking University.

Historically, clinical trials and population health studies have focused on white European participants, neglecting the diversity of other racial and ethnic groups. This partnership addresses the need to study underrepresented ethnic groups to improve our understanding of health and disease and will generate robust evidence on the lifestyle, environmental, and genetic factors influencing a wide range of common diseases. The insights gained from this study will be instrumental in advancing global efforts in disease prevention, risk prediction, and treatment. 

“Metabolomics offers a comprehensive representation of the phenotype and enhances multiomics research by linking gene expression to physiology. This connection strengthens researchers’ ability to accurately identify molecular entities and key biochemical pathways,” explained Kari Wong, Scientific Strategy Director at Metabolon. “To truly grasp ‘what’s occurring in large cohort studies, metabolomic data must be included, as metabolite levels uniquely reveal the factors influencing phenotype, including genetics, diet, environment, disease, drug exposure, and the microbiome.”

Initially, the assay will cover 4000 samples that will be linked to other available multiomics data, such as genotyping and proteomics. “We are excited by the opportunity for novel discovery by Metabolon’s Global Discovery Panel™, which is uniquely suited to help address many unanswered and complex research questions about the etiology of common diseases,” said Zhengming Chen, Richard Peto Professor of Epidemiology from Oxford Population Health. “The study will provide critical evidence to inform future scaling up of metabolomics assays in CKB and other large cohort studies in diverse populations, which may eventually lead to more tailored approaches to the prevention and treatment of different diseases.”

This partnership showcases Metabolon’s ability to profile large, diverse cohorts and play a leading role in multiomics research.

For more information, please visit:

About Metabolon
Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other ‘omics’ technologies. With more than 20 years, 15,000+ projects, 3,500+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Metabolon’s Global Discovery Panel is powered by the world’s largest proprietary metabolomics reference library. Metabolon’s industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, that support customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.

About Metabolomics
Metabolomics, the large-scale study of all small molecules in a biological system, is the only omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic and external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug’s mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.

iRegene Therapeutics Secures Series B+ Financing Following FDA Fast Track Designation for its Flagship Product NouvNeu001

CHENGDU, China, Sept. 9, 2025 /PRNewswire/ — iRegene Therapeutics (Chengdu) Co., Ltd. (“iRegene” or the “Company”), a biotechnology company pioneering chemically induced allogeneic cell therapy, announced on September 4th the successful completion of its Series B+ financing round, co-led by Northern Light Venture Capital, Chuangjing Capital, and OneHealth Haihe Capital, along with participation from other investors. In August 2025, NouvNeu001 received Fast Track Designation (FTD) from the U.S. FDA, making it the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to achieve this milestone.

This round builds on a series of sizable financings completed in recent months, bringing iRegene’s total funding to over RMB 300 million (~USD 40M). It makes the largest single financing in China’s iPSC sector in recent years, highlighting the strong confidence of investor in iRegene’s leadership position and long-term strategic vision.

The proceeds will be used to accelerate iRegene’s global clinical development of NouvNeu001 for Parkinson’s disease (PD), and NouvSight001 for retinal degenerative diseases, while also strengthening early-stage R&D, expanding clinical and operational teams, and advancing iRegene’s manufacturing capabilities.

About NouvNeu001

iRegene’s flagship product, NouvNeu001, is the world’s first clinical-stage, iPSC-derived, allogeneic dopaminergic progenitor cell therapy for PD. NouvNeu001 received the China NMPA’s IND clearance to initiate Phase I/II in China in Aug 2023, and received the FDA IND clearance to initiate Phase I in USA in June 2024. In April 2025, iRegene launched a multicenter Phase II clinical trial in China (NCT06167681).

Phase I results demonstrated:

  • Excellent safety and tolerability observed up to 15 months post-transplantation, notably without the use of immunosuppressants after the 6th months.
  • PET imaging confirmed long-term engraftment and survival of transplanted cells.
  • Significant clinical efficacy, including marked improvement in MDS-UPDRS Part III motor scores and extended “on-time” duration, underscoring the strong competitiveness.

On August 15, 2025, NouvNeu001 was granted Fast Track Designation (FTD) from the U.S. FDA, becoming the first allogeneic iPSC-derived PD cell therapy worldwide to earn this recognition. This milestone follows the FDA’s Special Exemption (SE) granted in March 2024, further validating iRegene’s clinical data integrity, product quality system, and innovative therapeutic approach.

Key Development Timeline for NouvNeu001

Date

Milestone

Aug 3, 2023

NMPA approved Phase I/II trial in China for moderate-to-advanced PD.

Dec 2023

First patient dosed at Beijing Hospital, National Center for Geriatrics.

Mar 2024

FDA granted Special Exemption.

Jun 2024

FDA IND approval for international multicenter Phase I trials.

Nov 2024

Phase I enrollment in China completed.

Apr 2025

Phase II trial launched in China.

Jul 2025

First Phase II patients dosed.

Aug 15, 2025

FDA granted Fast Track Designation (FTD).

CEO Statement

“We are deeply grateful for the trust and continued support of our investors, as well as the dedication of the iRegene team,” said Dr. Jun Wei, Founder and CEO of iRegene Therapeutics. “Our mission is to pioneer transformative therapies that truly reverse disease progression for patients worldwide. This financing will accelerate our global clinical programs, expand iRegene manufacturing capabilities, and advance our international footprint expansion, bringing us closer to delivering these life-changing therapies to the patients.”

About iRegene Therapeutics

Founded in 2017 by a team of international professionals, iRegene Therapeutics is the earliest biotech in the world to apply “Chemical induction” to precisely reprogram cell fate and optimize cellular functions. Leveraging this breakthrough platform, iRegene Therapeutics has built a robust pipeline targeting currently “incurable” diseases such as Parkinson’s disease and blindness. As a leader in chemical induction, iRegene’s proprietary system enables the efficient easy generation of human specific cell types with high purity, and enhanced functionality, pioneering the next generation of chemically derived cell therapies.

MAMMOTION’s Breakthrough Lawn Care Robotics Win Over 10 Awards at IFA 2025

The cutting-edge technology and sleek design of MAMMOTION’s autonomous lawn care products earned top industry honors at the world’s leading tech show

BERLIN, Sept. 9, 2025 /PRNewswire/ — MAMMOTION, a pioneer in intelligent outdoor robotics, captured overwhelming industry recognition at the IFA 2025 conference, earning over 10 awards from leading media outlets and industry experts—including the IFA Innovation Award. The company’s latest innovations — the LUBA mini AWD LiDAR robotic lawn mower, which is equipped with the world’s first integrated positioning system combining LiDAR, RTK and AI-powered vision technology — were central to this achievement, further consolidating the company’s leadership in extending the frontiers of autonomous lawn care.

LUBA mini AWD LiDAR and YUKA mini Vision swept IFA 2025 honors
LUBA mini AWD LiDAR and YUKA mini Vision swept IFA 2025 honors

LUBA mini AWD LiDAR: The World’s First Three-in-One Positioning Robotic Lawn Mower Won 2025 IFA Innovation Award

Unveiled at IFA 2025, MAMMOTION’s Tri-Fusion Positioning System — a revolutionary positioning and navigation platform that seamlessly integrates LiDAR, RTK and AI-powered Vision technology — captivated the industry with its unprecedented ability to dynamically adapt to all scenarios while maintaining consistent ±1 cm precision. This future-proofed system was first equipped on the company’s latest LUBA mini AWD LiDAR Series, which was recognized as the 2025 IFA Innovation Honoree Award for Best in Smart Home.

The innovation has also garnered multiple “Best of IFA 2025” and “Editor’s Choice” awards from leading global tech media. CHIP highlighted that it is an exciting development on last year’s best, the LUBA 2 AWD, incorporating LiDAR technology that “makes it particularly suitable for gardens with complex, shady or hilly lawns“. Computer Bild was also impressed by the novel platform, awarding it for “mapping the yard with centimeter precision in just a few minutes and detecting obstacles with ease”. TrustedReviews shared this sentiment by rewarding the “Best in Show” honor specifically to the Tri-Fusion Positioning System, remarking that it “delivers a new standard of precision and adaptability“. The buzz continued with Android Authority, Netzwelt, GameStar, The Ambient, Reviewed, inside digital and Stuff, with high praise from editors being given for “this robot lawnmower has the smartest navigation system I’ve seen on any robot mower”.

The YUKA mini Vision Series, MAMMOTION’s first pure vision-powered robot mower designed for small to medium gardens, was also a standout highlight at IFA 2025, receiving substantial acclaim from tech media outlets such as Techlicious, PC Welt and Frandroid. Featuring a three-camera vision system, the YUKA Mini Vision reimagines the mowing experience for homeowners, offering zero installation, auto-mapping and instant precision for a ‘Drop-and-Mow’ journey. As Techlicious IFA 2025 Editor’s Choice Award lauded, the new YUKA “opens the door for more people to try hands-free mowing without the typical frustration“.

“At MAMMOTION, we firmly believe in being the catalyst for change. We build intelligent robotics that are not just equipment, but solutions engineered to anticipate challenges, save time and respect the diversified environments in which they work”, said Jayden Wei, CEO of MAMMOTION. “We are deeply honored to receive such an overwhelming response from IFA and the global tech community. This marks an extremely encouraging start to MAMMOTION’s 10th year, as we continue our journey towards more accessible and transformative outdoor robotic technology for all.”

For more information, visit www.mammotion.com

About MAMMOTION

MAMMOTION is dedicated to creating intelligent, high-quality, and eco-friendly outdoor solutions through innovative robotics. As the maker of the award-winning LUBA 2 AWD Series—named one of TIME’s Best Inventions of 2024—and the versatile YUKA Series, MAMMOTION has transformed robotic lawn care for professionals and homeowners alike. With its new robotic pool cleaning product, the company is expanding its smart garden robotics lineup beyond lawns to pools, continuing its mission to make backyard maintenance easier, smarter, and more sustainable.

Stamus Networks Announces Production-Ready Clear NDR Community 1.0

The open-source edition of the company’s network detection and response (NDR) solution incorporates Suricata 8 and empowers AI security operations with integrated model context protocol (MCP)

INDIANAPOLIS and PARIS, Sept. 9, 2025 /PRNewswire/ — Stamus Networks, a global provider of high-performance network-based threat detection and response systems, today announced the general availability of Clear NDR® Community 1.0, marking the open-source solution’s official production-ready status. This release transforms the popular Suricata-based open-source security monitoring platform with significant enhancements in deployment flexibility, threat intelligence integration, AI integration, and incident investigation capabilities.

Clear NDR Community 1.0 builds upon last year’s initial beta release with a more robust architecture, expanded deployment options, and workflow improvements that make it suitable for production environments in small-to-medium sized organizations as well as researchers, educators, students, and hobbyists who wish to explore what is possible with Suricata and the network protocol monitoring logs and alerts it produces.

“With Clear NDR Community 1.0, we’re delivering on our promise to provide the most complete open and transparent network security solution that organizations can trust for many smaller environments,” said Peter Manev, co-founder and chief strategy officer at Stamus Networks. “As the only open source NDR on the market, and the only one with Suricata 8 and AI-native interfaces, it is uniquely positioned to help security teams experience the power of deep network visibility before considering an upgrade to our Enterprise edition.”

Expanded Deployment Options

Clear NDR Community 1.0 introduces multiple deployment options to accommodate diverse infrastructure requirements:

  • Debian ISO with Desktop environment – for those who prefer a graphical interface
  • Debian ISO without Desktop environment – for headless server deployments
  • Containerized version for any Linux environment – continuing support for Docker containerized deployments

These options enable deployment on bare metal hardware or virtual machines, providing greater flexibility than the Docker-only format available in the previous beta release.

Key Enhancements in Version 1.0

Clear NDR Community 1.0 includes several significant improvements:

  • Production-Grade Foundation: Upgraded to OpenSearch 2.0 data lake for enhanced performance and reliability
  • Built on Suricata 8.0: The latest version of Suricata delivers better threat detection accuracy, improved performance at scale, and expanded protocol coverage
  • Model Context Protocol (MCP): Standardized interfaces to enable integration of third-party generative and agentic AI
  • New Dashboards and Visualizations: Over 400 visualizations and 58 new dashboards for enhanced Suricata 8 network data
  • Streamlined Threat Intelligence: Native ability to ingest threat intelligence feeds without writing custom Suricata rules
  • Advanced Data Management: New facilities to help users control data retention
  • Accelerated Investigation: “Two-Click to Evidence” workflow that speeds incident response
  • External Integration: UI integration with other systems via configurable Deep Linking
  • Notification System: Keeps users informed of new releases and best practices

Supporting the Security Community

Clear NDR Community is widely used by network security practitioners, researchers, educators, students, and hobbyists to explore what’s possible with Suricata IDS/IPS/NSM and the network protocol monitoring logs and alerts it produces. Version 1.0 continues this tradition while offering even more capabilities for experimentation and learning.

“We believe in the power of open security tools to advance the industry’s collective defense capabilities,” added Peter Manev. “Clear NDR Community 1.0 represents our commitment to supporting both professional security teams in smaller organizations and the broader community of security enthusiasts.”

Enterprise Capabilities Available

For organizations requiring enterprise-scale deployments, Stamus Networks offers Clear NDR Enterprise, which builds upon the Community edition with additional capabilities for large-scale environments with high-fidelity security and compliance incident detection, machine learning and additional AI capabilities, advanced threat hunting, and automated response workflows.

Availability

Clear NDR Community 1.0 is available for download beginning immediately, from the Stamus Networks website. For more information, visit www.stamus-networks.com/clear-ndr-community.

Join one of the following webinars to learn more:

About Stamus Networks

Stamus Networks believes that cyber defense is bigger than any single person, platform, company, or technology. That’s why we leverage the power of community to deliver the next generation of open and transparent network defense. Trusted by security teams at the world’s most targeted organizations, our flagship offering – Clear NDR® – empowers cyber defenders to uncover and stop serious threats and unauthorized network activity before they harm their organizations. Clear NDR helps defenders see more clearly and act more confidently through detection they can trust with results they can explain. For more information visit www.stamus-networks.com.

Wild Turkey Bourbon Reveals New Global Campaign, Proudly Declaring “When You Know It’s Right, Don’t Change a Damn Thing”

New creative from Director Kiku Ohe and GUT New York pays homage to the brand’s unwavering conviction and time-tested recipe

LAWRENCEBURG, Ky., Sept. 9, 2025 /PRNewswire/ — In a world where trends come and go in the blink of an eye, Wild Turkey, the award-winning Kentucky bourbon brand, is drawing a line with the launch of its new global campaign: “When You Know It’s Right, Don’t Change a Damn Thing.”

These days, there’s always a new version and endless pressure to chase what’s next. But what good is change for change’s sake? While some may call it stubborn, Wild Turkey calls it conviction, and it’s how they’ve been making bourbon for over 100 years. This message is clear throughout the new campaign films, launching globally this month, as an unmistakable line is drawn on the ground. Wild Turkey has been faithful to its recipe for over a century and, with it, has created a legend.

At the heart of the story is an iconic heritage brand helmed by legendary Wild Turkey Master Distiller and Bourbon Hall of Famer Jimmy Russell, who helped save bourbon from a fate worse than death: becoming like everything else. In the 1970s and 1980s, when the industry turned toward lighter spirits, Jimmy refused to bend to fleeting fads and water down his signature Wild Turkey 101 bourbon. He kept making his bourbon the same way, aged longer and full of bold, pre-prohibition flavor. Today, Jimmy is celebrating 71 years with Wild Turkey, as the longest serving master distiller in the spirits industry. He is joined by his son, Master Distiller and Bourbon Hall of Famer Eddie Russell, and grandson, associate master blender Bruce Russell, to carry the recipe of Wild Turkey forward.

The campaign is an homage to the time-honored and the enduring, including classics like Wild Turkey 101 Bourbon, which still has the same signature bold flavor as it did over a century ago. The creative treatment for the campaign films, directed by Kiku Ohe, reflects this message. Featuring a compelling mixed-media approach incorporating film stock (8mm/35/Digital), digital and historical photos and artifacts. Reinforced by memorabilia from Jimmy’s seven decades in the industry – including old notebooks filled with recipes, newspaper clippings, and archival family photos – these pieces illustrate the brand’s rich history, heritage, and philosophy.

“Every bottle of Wild Turkey bourbon tells a story of conviction,” says Raul Gonzalez, Global Managing Director of Whiskey & Rum at Campari Group. “The brand’s steadfast approach is one reason why Wild Turkey is so beloved and respected all over the world today. There’s pride in ordering Wild Turkey bourbon, and we’re excited to bring Jimmy and Wild Turkey’s story to a new generation of fans with this new campaign.”

The campaign features notable cameos from four members of the Russell family including Master Distiller Jimmy Russell, his son Master Distiller Eddie Russell, his grandson Associate Blender Bruce Russell, and Jimmy’s granddaughter and Wild Turkey US Brand Ambassador Joann Street. The films also include bartenders and fans of Wild Turkey from some of the brand’s top global markets including Toure Folkes from New Orleans, US, Sam Russ from Brisbane, Australia and Naoto Ogawa from Tokyo, Japan.

“Wild Turkey is a brand that knows exactly who it is and refuses to compromise,” said Lucas Bongioanni, Chief Creative Officer, GUT New York. “In an era obsessed with innovation and reinvention, it’s rare to find a story that’s about staying true to its origins. We are honored to bring that special kind of bravery to life in a way that feels as bold as the bourbon itself.”

The first new global brand campaign since “Trust Your Spirit” debuted in 2021, “When You Know It’s Right, Don’t Change a Damn Thing” will begin to roll out in global markets in fall 2025, starting with the US, Japan, Australia, and South Korea. The campaign includes a variety of films and bold key visuals to be used across channels, including digital, social, TVC, and print.

For more information, visit wildturkeybourbon.com or follow Wild Turkey at @wildturkey.

ABOUT WILD TURKEY

The distillery for Wild Turkey Bourbon is in Kentucky, situated on a deep limestone shelf on the Kentucky River. The shelf acts as a natural filter and provides the distillery with crystal clear water, vital to making such a high-quality product. Wild Turkey features the legendary father and son Master Distilling team of Jimmy and Eddie Russell, who have over 100 years of collective experience working at the Wild Turkey distillery, and are now joined by the next generation, Associate Blender Bruce Russell.

The famous Wild Turkey brand name first came about back in 1940 when distillery executive Thomas McCarthey took a few warehouse samples on a Wild Turkey hunting trip with a group of friends. The following year, his friends asked him for “some of that Wild Turkey whiskey” and the brand was born.

Wild Turkey is distilled and put into new oak barrels at a much lower ABV than most bourbons. This results in a much richer flavor, as less is cooked out during the production process. Ageing in the highest quality new American oak barrels with the heaviest char available (the Number 4 “alligator” char), imparts a smooth flavor and deep amber color to the whiskey. The barrels are filled at the distillery in Lawrenceburg, Kentucky. Website: wildturkey.com.

ABOUT CAMPARI GROUP
Campari Group is a major player in the global spirits industry, with a portfolio of over 50 premium and super premium brands, spanning across Aperitifs, including iconic brands like Aperol and Campari, Agave spirits such as Espolòn tequila, Whiskeys and Rum, with Wild Turkey and Appleton Estate, as well as Cognac and Champagne, including Courvoisier and Grand Marnier. The Group was founded in 1860 and today is the sixth-largest player worldwide in the premium spirits industry. It has a global distribution reach, trading in over 190 nations around the world with leading positions in Europe and the Americas. Headquartered in Milan, Italy, Campari Group operates via 24 production sites worldwide and its own distribution network in 27 countries. Campari Group employs approximately 5,000 people. The shares of the parent company Davide Campari-Milano N.V. (Reuters CPRI.MI – Bloomberg CPR IM) have been listed on the Italian Stock Exchange since 2001. For more information: http://www.camparigroup.com/en. Please enjoy our brands responsibly.

When You Know It's Right, Don't Change A Damn Thing
When You Know It’s Right, Don’t Change A Damn Thing

 

Video – https://www.youtube.com/watch?v=z1Ok7CV4PBU 
Photo – https://laotiantimes.com/wp-content/uploads/2025/09/wild_turkey_when_you_know_it_s_right_don_t_change_a_damn_thing.jpg 
Logo – https://laotiantimes.com/wp-content/uploads/2025/09/wild_turkey_logo.jpg 

 

ZeroBounce ONE™ Debuts as All-in-One Email Deliverability Suite to Help Companies Land in the Inbox

New flagship subscription brings enterprise-level tools to businesses of all sizes

SANTA BARBARA, Calif., Sept. 9, 2025 /PRNewswire/ — Email validation and deliverability platform ZeroBounce today announced the launch of ZeroBounce ONE™, a flagship subscription that brings together its entire suite of deliverability tools – plus 25,000 monthly email validation credits – at a price lower than what the credits alone used to cost.

ZeroBounce ONE™ offers a simplified way to access the full ZeroBounce platform at a lower cost.
ZeroBounce ONE™ offers a simplified way to access the full ZeroBounce platform at a lower cost.

Previously, 25,000 validation credits cost $175 per month. Now, for just $99 per month (or $79 per month billed annually), ZeroBounce ONE customers gain not only the same 25,000 credits, but also a comprehensive toolkit that includes Email Warmup, DMARC Monitor, Blacklist Monitor, Inbox Placement Testing, Email Server Testing, and Email Finder – at no additional cost.

“At a time when many SaaS subscriptions are soaring in price, ZeroBounce ONE defies the trend and sets a new standard for value,” said Liviu Tanase, founder and CEO of ZeroBounce. “We’ve made enterprise-grade deliverability tools affordable and accessible to every marketer. Our mission has always been to help businesses land in the inbox, and now we’re giving them more than ever – for less than they were already paying.”

With inbox placement becoming increasingly difficult due to stricter filters and rising customer acquisition costs, ZeroBounce ONE aims to simplify and democratize access to deliverability tools that were once reserved for large enterprises. By unifying validation and deliverability into a single subscription, the plan eliminates the need for multiple services, helping businesses improve their email ROI.

Brian Minick, COO of ZeroBounce, added: “Marketers kept telling us deliverability tools felt expensive and fragmented as they had to use separate vendors. ZeroBounce ONE unifies everything into one subscription so businesses don’t have to choose between validation and deliverability – they get both, plus a 15% discount on any additional credits. It’s simple, powerful, and designed to help our customers succeed.”

ZeroBounce ONE includes:

  • 25,000 monthly email validation credits (credits never expire and roll over)
  • 10,000 monthly Email Finder/domain searches
  • 100 Inbox Placement Test
  • 100 Email Server Tests
  • 1 DMARC Monitor domain
  • 10 Blacklist Monitors
  • Inbox Warmup (2 accounts, 250 daily warmup actions)
  • A 15% discount on additional Pay-As-You-Go and Autopay credit purchases

Available now, ZeroBounce ONE offers a simplified way to access the full ZeroBounce platform, with flexible add-ons for scaling and an annual option that provides an additional 20% discount.

For more information, visit https://www.zerobounce.net/zerobounce-one. 

About ZeroBounce

ZeroBounce is an email validation and deliverability platform helping more than 500,000 customers worldwide land in the inbox. Its tools include email validation, email scoring, inbox placement testing, blacklist monitoring, DMARC monitoring, and more. ZeroBounce validates more than 6 billion emails annually and is widely recognized for its 99.6% accuracy rate, strong security standards, and award-winning customer support.

Media contact:

Corina Leslie
PR Manager
support@zerobounce.net